HMNC Brain Health is a Munich-based clinical-stage biopharmaceutical company developing personalized precision psychiatry treatments powered by AI and pharmacogenomics. Its pipeline includes two lead depression programs, one of which is an oral esketamine formulation being developed as a more convenient alternative to Johnson & Johnson's Spravato, and a separate novel mechanism in treatment-resistant depression. The company is leveraging companion-diagnostic and digital-phenotyping tools to stratify patients and improve response rates in major depressive disorder.
Company Info
Funding & Investor Relations
None publicly disclosed; clinical-stage European CNS biotech.
Upcoming Milestones & Key Dates
Initiation of HMNC-OES Phase 3 enabling studies
First AI-stratified Phase 2 efficacy readout in MDD
Clinical Development Pipeline
Recent News
Munich-based HMNC Brain Health closed a $50M Series B to advance two depression programs, including an oral esketamine challenger designed to compete with J&J's Spravato on convenience and access.
Munich-based HMNC Brain Health raises $50M in Series B funding to advance two depression drug candidates, including one positioned as a challenger to Johnson & Johnson's Spravato.
Leadership Team
Co-Founder and Chief Executive Officer
Chief Medical Officer
Chief Scientific Officer
Careers & Job Openings